

Anirban Basu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9210790/publications.pdf>

Version: 2024-02-01

141
papers

7,295
citations

136950

32
h-index

60623

81
g-index

147
all docs

147
docs citations

147
times ranked

9390
citing authors

#	ARTICLE	IF	CITATIONS
1	Public spending on acute and long-term care for Alzheimer's disease and related dementias. <i>Alzheimer's and Dementia</i> , 2023, 19, 150-157.	0.8	2
2	Minimum Threshold of Bariatric Surgical Weight Loss for Initial Diabetes Remission. <i>Diabetes Care</i> , 2022, 45, 92-99.	8.6	23
3	Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review. <i>Value in Health</i> , 2022, 25, 276-287.	0.3	3
4	The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach. <i>BMC Psychiatry</i> , 2022, 22, 32.	2.6	11
5	A sub-group evaluation of the multi-month dispensing strategy for differentiated HIV care: is personalization of care guidelines warranted in Haiti?. <i>BMC Health Services Research</i> , 2022, 22, 80.	2.2	2
6	Impact of a statewide Emergency Department Information Exchange on health care use and expenditures. <i>Health Services Research</i> , 2022, 57, 603-613.	2.0	4
7	Comparative effectiveness of gastric bypass and sleeve gastrectomy on predicted 10-year risk of cardiovascular disease 5 years after surgery. <i>Surgery for Obesity and Related Diseases</i> , 2022, , .	1.2	4
8	Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis. <i>PharmacoEconomics - Open</i> , 2022, 6, 469-481.	1.8	14
9	Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease. <i>PLoS ONE</i> , 2022, 17, e0267448.	2.5	4
10	Application of validated mapping algorithms between generic PedsQL scores and utility values to individuals with sickle cell disease. <i>Quality of Life Research</i> , 2022, 31, 2729-2738.	3.1	2
11	Exploring Medication Adherence with P2Y12 Inhibitors Using Conditional and Unconditional Quantile Regression Approaches. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 193-204.	2.2	1
12	Meta-analyzing count events over varying durations using the piecewise Poisson model: The case for poststroke seizures. <i>Research Synthesis Methods</i> , 2021, 12, 347-356.	8.7	0
13	Difficulty with Taking Medications Is Associated with Future Diagnosis of Alzheimer's Disease and Related Dementias. <i>Journal of General Internal Medicine</i> , 2021, 36, 863-868.	2.6	5
14	Improving risk adjustment with machine learning: accounting for service-level propensity scores to reduce service-level selection. <i>Health Services and Outcomes Research Methodology</i> , 2021, 21, 363-388.	1.8	2
15	Do pharmaceutical prices rise anticipating branded competition?. <i>Health Economics (United Kingdom)</i> , 2021, 30, 1070-1081.	1.7	0
16	Estimating Endogenous Treatment Effects Using Latent Factor Models with and without Instrumental Variables. <i>Econometrics</i> , 2021, 9, 14.	0.9	2
17	Real-world patterns on tumor mutation burden testing in a pan-tumor population. <i>Future Oncology</i> , 2021, 17, 1879-1887.	2.4	1
18	Quality-Adjusted Life-Year Losses Averted With Every COVID-19 Infection Prevented in the United States. <i>Value in Health</i> , 2021, 24, 632-640.	0.3	13

#	ARTICLE	IF	CITATIONS
19	Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018. JAMA Network Open, 2021, 4, e2113393.	5.9	8
20	Catalog of Age- and Medical Conditionâ€™Specific Healthcare Costs in the United States to Inform Future Costs Calculations in Cost-Effectiveness Analysis. Value in Health, 2021, 24, 957-965.	0.3	9
21	The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature. Pharmacoeconomics, 2021, 39, 1225-1241.	3.3	7
22	Protocol for an observational cohort study investigating personalised medicine for intensification of treatment in people with type 2 diabetes mellitus: the PERMIT study. BMJ Open, 2021, 11, e046912.	1.9	1
23	Comparative Effectiveness of Gastric Bypass and Vertical Sleeve Gastrectomy for Hypertension Remission and Relapse: The ENGAGE CVD Study. Hypertension, 2021, 78, 1116-1125.	2.7	15
24	Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 95-104.	0.9	1
25	A Value-of-Information Framework for Personalizing the Timing of Surveillance Testing. Medical Decision Making, 2021, , 0272989X2110492.	2.4	0
26	Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study. Pharmacoeconomics, 2020, 38, 57-68.	3.3	22
27	Providers' perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qualitative assessment. Research in Social and Administrative Pharmacy, 2020, 16, 1033-1040.	3.0	13
28	Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment. Pharmacoeconomics, 2020, 38, 171-179.	3.3	0
29	Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis. Value in Health, 2020, 23, 96-103.	0.3	25
30	Washington's privatization of liquor: effects on household alcohol purchases from Initiative 1183. Addiction, 2020, 115, 681-689.	3.3	5
31	Regression Discontinuity Design. JAMA - Journal of the American Medical Association, 2020, 324, 381.	7.4	33
32	Provider preferences for resolving uncertainty and avoiding harms in precision medicine: a discrete choice experiment. Personalized Medicine, 2020, 17, 389-398.	1.5	2
33	Estimating The Infection Fatality Rate Among Symptomatic COVID-19 Cases In The United States. Health Affairs, 2020, 39, 1229-1236.	5.2	97
34	Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 529-537.	0.9	10
35	Evidence generation, decision making, and consequent growth in health disparities. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 14042-14051.	7.1	2
36	Health Economics Tools and Precision Medicine: Opportunities and Challenges. Forum for Health Economics and Policy, 2020, 23, .	0.8	8

#	ARTICLE	IF	CITATIONS
37	Assessing Health Care Burden in Glaucoma Patients with and Without Physical or Mental Comorbidities. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 325-331.	0.9	1
38	Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. <i>Value in Health</i> , 2020, 23, 139-150.	0.3	105
39	A welfare-theoretic model consistent with the practice of cost-effectiveness analysis and its implications. <i>Journal of Health Economics</i> , 2020, 70, 102287.	2.7	10
40	Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. <i>Value in Health</i> , 2020, 23, 277-286.	0.3	75
41	Effectiveness of Gastric Bypass Versus Gastric Sleeve for Cardiovascular Disease: Protocol and Baseline Results for a Comparative Effectiveness Study. <i>JMIR Research Protocols</i> , 2020, 9, e14936.	1.0	8
42	Time Horizons in Cost Analyses—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 582.	7.4	0
43	Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013. <i>Pharmacoeconomics</i> , 2019, 37, 1287-1300.	3.3	2
44	Implementation evaluation of academic detailing on naloxone prescribing trends at the United States Veterans Health Administration. <i>Health Services Research</i> , 2019, 54, 1055-1064.	2.0	28
45	Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States. <i>Pharmacoeconomics</i> , 2019, 37, 1321-1327.	3.3	8
46	Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy. <i>Value in Health</i> , 2019, 22, 988-994.	0.3	2
47	Postdischarge Unplanned Care Events Among Commercially Insured Patients With an Observation Stay Versus Short Inpatient Admission. <i>Annals of Emergency Medicine</i> , 2019, 74, 334-344.	0.6	1
48	Development and Validation of the Real-World Progression in Diabetes (RAPIDS) Model. <i>Medical Decision Making</i> , 2019, 39, 137-151.	2.4	4
49	How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma. <i>Value in Health</i> , 2019, 22, 777-784.	0.3	14
50	Do cancer treatments have option value? Real-world evidence from metastatic melanoma. <i>Health Economics (United Kingdom)</i> , 2019, 28, 855-867.	1.7	15
51	Medicare expenditures attributable to dementia. <i>Health Services Research</i> , 2019, 54, 773-781.	2.0	33
52	Overview of Cost-effectiveness Analysis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1400.	7.4	71
53	Analysis of Benefit of Intensive Care Unit Transfer for Deteriorating Ward Patients. <i>JAMA Network Open</i> , 2019, 2, e187704.	5.9	20
54	Choosing a Time Horizon in Cost and Cost-effectiveness Analyses. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1096.	7.4	33

#	ARTICLE	IF	CITATIONS
55	Health Returns to Pharmaceutical Innovation in the Market for Oral Chemotherapy in Response to Insurance Coverage Expansion. <i>American Journal of Health Economics</i> , 2019, 5, 360-375.	3.0	2
56	How can clinical researchers quantify the value of their proposed comparative research?. <i>American Heart Journal</i> , 2019, 209, 116-125.	2.7	2
57	Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]. <i>Value in Health</i> , 2018, 21, 131-139.	0.3	321
58	A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]. <i>Value in Health</i> , 2018, 21, 161-165.	0.3	113
59	Alternative evaluation metrics for risk adjustment methods. <i>Health Economics (United Kingdom)</i> , 2018, 27, 984-1010.	1.7	13
60	Approaches to Aggregation and Decision Making—A Health Economics Approach: An ISPOR Special Task Force Report [5]. <i>Value in Health</i> , 2018, 21, 146-154.	0.3	59
61	<scp>2SLS</scp> versus <scp>2SRI</scp>: <scp>A</scp>ppropriate methods for rare outcomes and/or rare exposures. <i>Health Economics (United Kingdom)</i> , 2018, 27, 937-955.	1.7	42
62	Decision Criterion and Value of Information Analysis: Optimal Aspirin Dosage for Secondary Prevention of Cardiovascular Events. <i>Medical Decision Making</i> , 2018, 38, 427-438.	2.4	10
63	Returns to scientific publications for pharmaceutical products in the United States. <i>Health Economics (United Kingdom)</i> , 2018, 27, 282-293.	1.7	2
64	Does Maternity Care Coordination Influence Perinatal Health Care Utilization? Evidence from North Carolina. <i>Health Services Research</i> , 2018, 53, 2368-2383.	2.0	20
65	Longitudinal trends and predictors of statin use among patients with diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 27-33.	2.3	14
66	Heterogeneity in the impact of type of schooling on adult health and lifestyle. <i>Journal of Health Economics</i> , 2018, 57, 1-14.	2.7	14
67	Association Between the Publication of Clinical Evidence and the Use of Bariatric Surgery. <i>Obesity Surgery</i> , 2018, 28, 1321-1328.	2.1	8
68	Comment: Manski's views on patient care under uncertainty. <i>Health Economics (United Kingdom)</i> , 2018, 27, 1422-1424.	1.7	0
69	Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy218.	0.9	7
70	The Value of Outpatient Imaging-Based Cancer Screening Episodes. <i>Journal of General Internal Medicine</i> , 2018, 33, 1571-1573.	2.6	7
71	Future Directions for Cost-effectiveness Analyses in Health and Medicine. <i>Medical Decision Making</i> , 2018, 38, 767-777.	2.4	58
72	The effect of prenatal exposure to Ramadan on children's height. <i>Economics and Human Biology</i> , 2018, 30, 69-83.	1.7	16

#	ARTICLE	IF	CITATIONS
73	Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study. <i>Cancer Medicine</i> , 2018, 7, 4251-4260.	2.8	8
74	Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 759-768.	0.9	9
75	Price elasticities of pharmaceuticals in a value based€formulary setting. <i>Health Economics (United) Tj ETQq1 1 0.784314 rgBT /Over</i>	1.7	12
76	Burden of illness and research investments in translational sciences for pharmaceuticals in metastatic cancers. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 15-24.	1.4	1
77	Toward a Hedonic Value Framework in Health Care. <i>Value in Health</i> , 2017, 20, 261-265.	0.3	8
78	Measuring the Value of Pharmaceuticals in the US Health System. <i>Pharmacoeconomics</i> , 2017, 35, 1-4.	3.3	10
79	New Metrics for Economic Evaluation in the Presence of Heterogeneity: Focusing on Evaluating Policy Alternatives Rather than Treatment Alternatives. <i>Medical Decision Making</i> , 2017, 37, 930-941.	2.4	8
80	Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures. <i>Medical Care</i> , 2017, 55, 191-198.	2.4	33
81	Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 1084-1090.	0.9	7
82	Impact of value of research analyses on SWOG€™s clinical trial capsule scoring.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18311-e18311.	1.6	0
83	Impact of a value-based formulary in three chronic disease cohorts. <i>American Journal of Managed Care</i> , 2017, 23, S46-S53.	1.1	4
84	Estimating Costs and Valuations of Non-Health Benefits in Cost-Effectiveness Analysis. , 2016, , 201-236.		23
85	Real-World Data. <i>Medical Care</i> , 2016, 54, 1038-1044.	2.4	5
86	Financing a Cure for Diabetes in a Multipayer Environment. <i>Value in Health</i> , 2016, 19, 861-868.	0.3	10
87	Transitional care clinics for follow-up and primary care linkage for patients discharged from the ED. <i>American Journal of Emergency Medicine</i> , 2016, 34, 1230-1235.	1.6	25
88	Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1093.	7.4	2,149
89	Real-World Data: Responses to Zito and Doshi. <i>Medical Care</i> , 2016, 54, 1048-1049.	2.4	0
90	Workplace Stress and Working from Home Influence Depressive Symptoms Among Employed Women with Young Children. <i>International Journal of Behavioral Medicine</i> , 2016, 23, 102-111.	1.7	51

#	ARTICLE	IF	CITATIONS
91	Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group. Medical Decision Making, 2016, 36, 641-651.	2.4	25
92	Individualization of Treatment and Comparative Effectiveness Research. , 2016, , 255-274.		0
93	In-Hospital Outcomes and Costs Among Patients Hospitalized During a Return Visit to the Emergency Department. JAMA - Journal of the American Medical Association, 2016, 315, 663.	7.4	90
94	Parental Predictions and Perceptions Regarding Long-Term Childhood Obesity-Related Health Risks. Academic Pediatrics, 2016, 16, 475-481.	2.0	13
95	A Framework for Prioritizing Research Investments in Precision Medicine. Medical Decision Making, 2016, 36, 567-580.	2.4	12
96	Person-centered Treatment (PeT) Effects: Individualized Treatment Effects Using Instrumental Variables. The Stata Journal, 2015, 15, 397-410.	2.2	6
97	Are Elderly Patients With Clinically Localized Prostate Cancer Overtreated? Exploring Heterogeneity in Survival Effects. Medical Care, 2015, 53, 79-86.	2.4	16
98	Welfare implications of learning through solicitation versus diversification in health care. Journal of Health Economics, 2015, 42, 165-173.	2.7	7
99	Financing cures in the United States. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 1-4.	1.4	21
100	Effects of Maternity Care Coordination on Pregnancy Outcomes: Propensity-Weighted Analyses. Maternal and Child Health Journal, 2015, 19, 121-127.	1.5	26
101	Individualization of Treatment and Comparative Effectiveness Research. , 2015, , 1-21.		0
102	Value of information analyses for real-time prioritization decisions within a cancer clinical trials cooperative group.. Journal of Clinical Oncology, 2015, 33, 6506-6506.	1.6	0
103	Predicting low accrual in the Clinical Trials Cooperative Group Program's phase II/III oncology trials.. Journal of Clinical Oncology, 2015, 33, 6522-6522.	1.6	0
104	RESPONSE TO EPSTEIN'S COMMENT ON "HETEROGENEITY IN ACTION" Health Economics (United Kingdom) 2014, 23, 359-373.	1.7	22
105	ESTIMATING PERSON-CENTERED TREATMENT (PeT) EFFECTS USING INSTRUMENTAL VARIABLES: AN APPLICATION TO EVALUATING PROSTATE CANCER TREATMENTS. Journal of Applied Econometrics, 2014, 29, 671-691.	2.3	38
106	HETEROGENEITY IN ACTION: THE ROLE OF PASSIVE PERSONALIZATION IN COMPARATIVE EFFECTIVENESS RESEARCH. Health Economics (United Kingdom), 2014, 23, 359-373.	1.7	22
107	CAN WE MAKE SMART CHOICES BETWEEN OLS AND CONTAMINATED IV METHODS?. Health Economics (United Kingdom), 2014, 23, 462-472.	1.7	13
108	Risk Stratification for Sudden Cardiac Death. Circulation, 2014, 129, 516-526.	1.6	131

#	ARTICLE	IF	CITATIONS
109	Trends in health-related quality of life (HRQoL) and income over time in older adults with and without cancer: Evidence from the Surveillance, Epidemiology, and End Resultsâ€“Medicare Health Outcomes Survey (SEERâ€“MHOS) linked database.. Journal of Clinical Oncology, 2014, 32, 9603-9603.	1.6	0
110	Irrelevance of explicit costâ€“effectiveness thresholds when coverage decisions can be reversed. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 163-165.	1.4	1
111	Personalized Medicine in the Context of Comparative Effectiveness Research. Forum for Health Economics and Policy, 2013, 16, S73-S86.	0.8	2
112	HIGHLIGHTING DIFFERENCES BETWEEN CONDITIONAL AND UNCONDITIONAL QUANTILE REGRESSION APPROACHES THROUGH AN APPLICATION TO ASSESS MEDICATION ADHERENCE. Health Economics (United Kingdom) 2010, 30, 985-1005 /Overl	0.0	0
113	Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs. Journal of Comparative Effectiveness Research, 2012, 1, 171-180.	1.4	3
114	Patientâ€“centered or â€“centralâ€“ patient: Raising the veil of ignorance over randomization. Statistics in Medicine, 2012, 31, 3057-3059.	1.6	2
115	Private Manufacturersâ€™ Thresholds to Invest in Comparative Effectiveness Trials. Pharmacoeconomics, 2012, 30, 859-868.	3.3	3
116	Regression Estimators for Generic Health-Related Quality of Life and Quality-Adjusted Life Years. Medical Decision Making, 2012, 32, 56-69.	2.4	122
117	Comparative Cost Analysis of Housing and Case Management Program for Chronically Ill Homeless Adults Compared to Usual Care. Health Services Research, 2012, 47, 523-543.	2.0	98
118	Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care. Journal of Health Economics, 2011, 30, 549-559.	2.7	60
119	The impact of comparative effectiveness research on health and health care spending. Journal of Health Economics, 2011, 30, 695-706.	2.7	36
120	Estimating treatment effects on healthcare costs under exogeneity: is there a â€“magic bulletâ€“?. Health Services and Outcomes Research Methodology, 2011, 11, 1-26.	1.8	26
121	Estimating Decision-Relevant Comparative Effects Using Instrumental Variables. Statistics in Biosciences, 2011, 3, 6-27.	1.2	19
122	Minimal Modeling Approaches to Value of Information Analysis for Health Research. Medical Decision Making, 2011, 31, E1-E22.	2.4	53
123	Estimating lifetime or episodeâ€“ofâ€“illness costs under censoring. Health Economics (United Kingdom), 2010, 19, 1010-1028.	1.7	64
124	Impact of Medicare Part D on Medicareâ€“Medicaid Dualâ€“Eligible Beneficiaries' Prescription Utilization and Expenditures. Health Services Research, 2010, 45, 133-151.	2.0	35
125	Forecasting Distribution of Body Mass Index in the United States: Is There More Room for Growth?. Medical Decision Making, 2010, 30, E1-E11.	2.4	25
126	A Time Tradeoff Method for Eliciting Partnerâ€“s Quality of Life due to Patientâ€“s Health States in Prostate Cancer. Medical Decision Making, 2010, 30, 355-365.	2.4	38

#	ARTICLE	IF	CITATIONS
127	The Economics of Comparative Effectiveness Studies. <i>Pharmacoeconomics</i> , 2010, 28, 843-853.	3.3	25
128	Quantitative Methods for Valuing Comparative Effectiveness Information. , 2010, 17, 2-10.		2
129	Comparative Effectiveness Research For Antipsychotic Medications: How Much Is Enough?. <i>Health Affairs</i> , 2009, 28, w794-w808.	5.2	16
130	Individualization at the Heart of Comparative Effectiveness Research: The Time for i-CER Has Come. <i>Medical Decision Making</i> , 2009, 29, NP9-NP11.	2.4	33
131	A linear index for predicting joint health states utilities from single health states utilities. <i>Health Economics (United Kingdom)</i> , 2009, 18, 403-419.	1.7	22
132	Issues for the Next Generation of Health Care Cost Analyses. <i>Medical Care</i> , 2009, 47, S109-S114.	2.4	110
133	Social costs of robbery and the cost effectiveness of substance abuse treatment. <i>Health Economics (United Kingdom)</i> , 2008, 17, 927-946.	1.7	32
134	Two-stage residual inclusion estimation: Addressing endogeneity in health econometric modeling. <i>Journal of Health Economics</i> , 2008, 27, 531-543.	2.7	1,212
135	Value of Information on Preference Heterogeneity and Individualized Care. <i>Medical Decision Making</i> , 2007, 27, 112-127.	2.4	117
136	Use of instrumental variables in the presence of heterogeneity and self-selection: an application to treatments of breast cancer patients. <i>Health Economics (United Kingdom)</i> , 2007, 16, 1133-1157.	1.7	149
137	Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. <i>Schizophrenia Research</i> , 2006, 86, 99-109.	2.0	32
138	Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach. <i>Statistics in Medicine</i> , 2006, 25, 2886-2910.	1.6	4
139	Scale of interest versus scale of estimation: comparing alternative estimators for the incremental costs of a comorbidity. <i>Health Economics (United Kingdom)</i> , 2006, 15, 1091-1107.	1.7	61
140	Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. <i>Biostatistics</i> , 2005, 6, 93-109.	1.5	302
141	Implications of spillover effects within the family for medical cost-effectiveness analysis. <i>Journal of Health Economics</i> , 2005, 24, 751-773.	2.7	137